Enasidenib (Idhifa)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).

Diseases for which it is used

History of changes in FDA indication

Also known as

  • Code names: AG-221, CC-90007
  • Brand name: Idhifa